Bonac Corporation (“Bonac”; HQ: Kurume City, Fukuoka; CEO: Hirotake Hayashi) is pleased to announce the proposal, "Development of Bonac Nucleic Acid Medicines Targeting the Receptor-Bound Prorenin System," has been selected as a grant project by the New Energy and Industrial Technology Development Organization (NEDO) for the "R&D Promotion Project for Bridging to Small and Medium-Sized Enterprises for FY2015.”

 

In this project, through joint research with Hokkaido University (Professor Susumu Ishida, Department of Ophthalmology), Bonac will utilize the technology of "Bonac Nucleic Acid" to develop a therapeutic drug for "uveitis," an intractable eye disease, targeting the receptor-bound prorenin system.

 

In the future, Bonac will further accelerate the development of next-generation drugs in the field of ophthalmology in collaboration with Tokyo Medical University (Dr. Masahiko Kuroda, Senior Professor, Department of Molecular Pathology) and Gifu Pharmaceutical University (Dr. Hirofumi Takeuchi, Professor, Department of Pharmaceutical Sciences), and promote research and development so that Bonac’s nucleic acid technology will serve as a bridge to drug discovery.　

 

Contact:

Corporate Affairs

press@bonac.co.jp